(1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …

Piperacillin/tazobactam (TZP) is administered intravenously in a fixed ratio (8: 1) with the
potential for inadequate tazobactam exposure to ensure piperacillin activity against …

Background Urosepsis caused by extended-spectrum β-lactamase (ESBL)-producing
Escherichia coli is increasing worldwide. Carbapenems are commonly recommended for the …

Background Limited data exist regarding the efficacy of piperacillin-tazobactam (TZP) for the
management of nonbacteremic pyelonephritis caused by extended-spectrum β-lactamase …

(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …

Piperacillin/tazobactam (TZP) as an alternative treatment to carbapenems for infections
involving extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) …

Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae pose a huge threat
to human health, especially in the context of complicated urinary tract infections (cUTIs) …

Carbapenems are recommended for the treatment of urosepsis caused by extended-
spectrum β-lactamase (ESBL)-producing, multidrug-resistant Escherichia coli; however, due …

(1) Objectives: To assess the impact of optimal joint pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam monotherapy …

Avibactam is a non-β-lactam β-lactamase inhibitor that has been approved in combination
with ceftazidime for the treatment of complicated intra-abdominal infections, complicated …